Jung, H.-S.; Kim, H.S.; Kang, J.S.; Kang, Y.H.; Sohn, H.J.; Byun, Y.; Han, Y.; Yun, W.-G.; Cho, Y.J.; Lee, M.;
et al. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers 2022, 14, 4360.
https://doi.org/10.3390/cancers14184360
AMA Style
Jung H-S, Kim HS, Kang JS, Kang YH, Sohn HJ, Byun Y, Han Y, Yun W-G, Cho YJ, Lee M,
et al. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers. 2022; 14(18):4360.
https://doi.org/10.3390/cancers14184360
Chicago/Turabian Style
Jung, Hye-Sol, Hyeong Seok Kim, Jae Seung Kang, Yoon Hyung Kang, Hee Ju Sohn, Yoonhyeong Byun, Youngmin Han, Won-Gun Yun, Young Jae Cho, Mirang Lee,
and et al. 2022. "Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis" Cancers 14, no. 18: 4360.
https://doi.org/10.3390/cancers14184360
APA Style
Jung, H.-S., Kim, H. S., Kang, J. S., Kang, Y. H., Sohn, H. J., Byun, Y., Han, Y., Yun, W.-G., Cho, Y. J., Lee, M., Kwon, W., & Jang, J.-Y.
(2022). Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 14(18), 4360.
https://doi.org/10.3390/cancers14184360
